News ArticleIs pharma R&D model flawed?
The MSF believes that pharma’s R&D model is flawed as it is predominantly driven by commercial rewards rather than health priorities. World health ministers recently met to decide whether or not to start the process to jumpstart R&D for unmet needs. These unmet needs include: more effective treatments for drug-resistant tuberculosis, paediatric versions of HIV drugs, and a test to determine whether a patient with Chagas disease has been cured. (Source: InPharm, 5/22/12)